Jacqueline Cloos

The effect of G-CSF on the in vitro cytotoxicity of cytarabine and fludarabine in the FLAG combination in pediatric acute myeloid leukemia.

Acquired resistance to chloroquine in human CEM T cells is mediated by multidrug resistance-associated protein 1 and provokes high levels of cross-resistance to glucocorticoids.

Microarray analysis of bleomycin-exposed lymphoblastoid cells for identifying cancer susceptibility genes.

Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples.

Sulfasalazine sensitises human monocytic/macrophage cells for glucocorticoids by upregulation of glucocorticoid receptor alpha and glucocorticoid induced apoptosis.

Methylenetetrahydrofolate reductase (MTHFR) C677T and thymidylate synthase promoter (TSER) polymorphisms in Indonesian children with and without leukemia.

Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein.

Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features.

Role of tyrosine phosphatase inhibitors in cancer treatment with emphasis on SH2 domain-containing tyrosine phosphatases (SHPs).

Attenuated AMPA receptor expression allows glioblastoma cell survival in glutamate-rich environment.

FLT3 and KIT mutated pediatric acute myeloid leukemia (AML) samples are sensitive in vitro to the tyrosine kinase inhibitor SU11657.

Strategies for the analysis of in vitro radiation sensitivity and prediction of interaction with potential radiation modifying agents.

High-frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: implications for personalized medicine.

In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma.

Evaluation of gene expression signatures predictive of cytogenetic and molecular subtypes of pediatric acute myeloid leukemia.

Down-regulation of miR-101 in endothelial cells promotes blood vessel formation through reduced repression of EZH2.

miR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesis.

Cell sensitivity assays: the MTT assay.

Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia.

Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer.

PARP inhibition sensitizes childhood high grade glioma, medulloblastoma and ependymoma to radiation.

Myeloid Antigen Expression in Childhood Acute Lymphoblastic Leukemia and Its Relevance for Clinical Outcome in Indonesian ALL-2006 Protocol.

Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors.

Randomized double blind trial of ciprofloxacin prophylaxis during induction treatment in childhood acute lymphoblastic leukemia in the WK-ALL protocol in Indonesia.

Proteasome inhibitors in acute leukemia.

Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors.

High resolution SNP array profiling identifies variability in retinoblastoma genome stability.

Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines.

Pre-B-cell leukemia homeobox interacting protein 1 is overexpressed in astrocytoma and promotes tumor cell growth and migration.

Anti-leukemic activity and mechanisms underlying resistance to the novel immunoproteasome inhibitor PR-924.

RB1 mutation spectrum in a comprehensive nationwide cohort of retinoblastoma patients.

Antileukemic activity and mechanism of drug resistance to the marine Salinispora tropica proteasome inhibitor salinosporamide A (Marizomib).

Relevance of leukemic stem cells in acute myeloid leukemia: heterogeneity and influence on disease monitoring, prognosis and treatment design.

Pre-mRNA splicing in cancer: the relevance in oncogenesis, treatment and drug resistance.

Molecular basis of resistance to proteasome inhibitors in hematological malignancies.

Gene expression profiles associated with pediatric relapsed AML.

Methotrexate resistance in relation to treatment outcome in childhood acute lymphoblastic leukemia.

Loss of photoreceptorness and gain of genomic alterations in retinoblastoma reveal tumor progression.

Multifactorial resistance to aminopeptidase inhibitor prodrug CHR2863 in myeloid leukemia cells: down-regulation of carboxylesterase 1, drug sequestration in lipid droplets and pro-survival activation ERK/Akt/mTOR.

Folylpolyglutamate synthetase splicing alterations in acute lymphoblastic leukemia are provoked by methotrexate and other chemotherapeutics and mediate chemoresistance.

Clinical Impact of Additional Cytogenetic Aberrations, cKIT and RAS Mutations, and Treatment Elements in Pediatric t(8;21)-AML: Results From an International Retrospective Study by the International Berlin-Frankfurt-Münster Study Group.

miR expression profiling at diagnosis predicts relapse in pediatric precursor B-cell acute lymphoblastic leukemia.

Pharmacodynamic monitoring of (immuno)proteasome inhibition during bortezomib treatment of a critically ill patient with lupus nephritis and myocarditis.

Exosomes Secreted by Apoptosis-Resistant Acute Myeloid Leukemia (AML) Blasts Harbor Regulatory Network Proteins Potentially Involved in Antagonism of Apoptosis.

How to assess minimal residual disease in pediatric and adult acute myeloid leukemia?

A chemical screen for medulloblastoma identifies quercetin as a putative radiosensitizer.

The association of aberrant folylpolyglutamate synthetase splicing with ex vivo methotrexate resistance and clinical outcome in childhood acute lymphoblastic leukemia.

A Meta-Analysis of Retinoblastoma Copy Numbers Refines the List of Possible Driver Genes Involved in Tumor Progression.

Somatic genomic alterations in retinoblastoma beyond RB1 are rare and limited to copy number changes.

Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors.

Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy.

Genomic landscape of retinoblastoma in Rbp130mice resembles human retinoblastoma.

Leukemic stem cells: identification and clinical application.

The interference of genetic associations in establishing the prognostic value of the immunophenotype in acute myeloid leukemia.

Bortezomib resistance in multiple myeloma is associated with increased serine synthesis.

(Immuno)proteasomes as therapeutic target in acute leukemia.

Leukaemic stem cell load at diagnosis predicts the development of relapse in young acute myeloid leukaemia patients.

Trimethylation of H3K27 during human cerebellar development in relation to medulloblastoma.

Positioning of proteasome inhibitors in therapy of solid malignancies.

Minimal/measurable residual disease in AML: consensus document from ELN MRD Working Party.

Proteasome inhibition and mechanism of resistance to a synthetic, library-based hexapeptide.